Insulin/IGF-I Signaling Pathway and the Metabolic Syndrome: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Joseph A. M. J. L. Janssen

The metabolic syndrome is a cluster of overlapping conditions resulting in an increased incidence of type 2 diabetes, cardiovascular disease, and cancer. Prevalence of the metabolic syndrome in the Western world has reached epidemic proportions and this is likely due to alterations in diet and the environment as well as decreased physical activity.

  • hyperinsulinemia
  • IGF-I
  • IGFBP-1
  • insulin resistance

1. Introduction

The metabolic syndrome (previously also called syndrome X and the insulin resistance syndrome) is characterized by a group of metabolic disturbances which are associated with an enhanced risk of type 2 diabetes, cardiovascular diseases, certain types of cancer, and mortality. Over the last fifty years, the metabolic syndrome in the Western world has reached epidemic proportions. Since the human genome has been virtually unchanged since 1950, the increased prevalence of the metabolic syndrome can be attributed to important environmental changes interacting with genes [1].
The “modern” Western diet is characterized by a high content of saturated fats, sugar, corn-derived fructose syrup, proteins (derived from fatty domesticated and processed meats), refined grains, low fiber content, salt, and reduced consumption of fruits and vegetables [2]. The “modern” Western diet and lifestyle may have played an important etiological role in the pathogenesis of the metabolic syndrome and its consequences.

2. The Insulin–IGF-I System

The insulin–IGF system is formed by insulin, two insulin-like growth factors (IGF-I and IGF-II), and six cell-membrane signal-transducing receptors (insulin receptor-A (IR-A), insulin receptor-B (IR-B), insulin-like growth factor-I receptor (IGF-IR) and their respective hybrids): the IRs and IGF-IR can be found at the cell surface as homodimers composed of two identical alpha/beta monomers, or as heterodimers composed of two different receptor monomers (aka hybrids) [3][4][5]. The system further contains the IGF-II scavenger transmembrane protein previously known as insulin-like growth factor “receptor”-II “(IGF2R), and six IGF-binding proteins (IGFBP-1-6), several IGFBP-related proteins and IGFBP proteases, which serve to tightly regulate IGF-I and IGF-II levels/bioavailability in circulation and at the cell surface [3][4][5][6][7][8]. Insulin and IGF-I show high structural similarities.
It has been postulated that IGF-I emerged at a very early stage in vertebrate evolution from an ancestral insulin-type gene [9]. This ancestral insulin-like gene was duplicated to form insulin and IGF-I in early (agnathan) vertebrates. Further gene duplications resulted in distinct IGF-I and IGF-II genes, which were first found during evolution in gnathosomes (jawed vertebrates) [10]. In vertebrates, insulin-like peptides predominantly functioned as growth factors promoting tissue growth and development. However, in vertebrates, this growth-promoting function has been subsumed by IGF-I and IGF-II, while insulin has acquired this new function and is primarily involved in metabolism. It has further been demonstrated that, in vertebrates, nutritional status is the key regulator of the activities of insulin and IGFs [11]. Consequently, insulin and IGFs regulate metabolism, growth and development in vertebrates in response to nutritional availability.
IGF-I displays approximately 50% structural homology with proinsulin [12]. In humans, insulin and IGF-I are transported in plasma and delivered to cell membrane receptors [13]. In contrast to insulin, IGF-I is mainly present in the plasma bound to six different binding proteins, the so-called IGFBPs. The IGFBPs act as transport proteins and control efflux from circulating IGF-I and IGF-II [13]. IGFBPs modulate interactions between the IGFs and the IGF-IR, thereby indirectly controlling the biological actions of IGF-I and IGF-II [13]. Because of the high affinity of IGF-I for IGFBPs, <1% of circulating plasma IGF-I is in a free form, whereas in contrast, insulin is largely in a free form [14]. Free IGF-I may be the major biologically active hormonal form of IGF-I [15]. When evaluating IGF-I bioactivity in health and disease, it is therefore recommended also to measure circulating free IGF-I levels [15].

3. The Role of Insulin and IGF-I in Metabolism

Insulin and IGF-I are both complementary and involved in metabolism, growth, and in the control of essential cellular and physiological processes such as proliferation, differentiation, and body growth [16]. Although insulin is, in many respects, structurally similar to IGF-I, insulin binds with high affinity to the insulin receptor, whereas it has very low affinity for the IGF-I receptor, while the converse is true for IGF-I [17]. Binding of IGF-I to the IGF-I receptor primarily results in stimulation of proliferation and differentiation of cells [17]. Nevertheless, IGF-I also stimulates insulin-like actions (glucose and amino acid uptake, mRNA, and protein synthesis) in cells and enhances insulin sensitivity [14][18]. Most of the ability of IGF-I to enhance insulin sensitivity is mediated (indirectly) through suppression of GH, a well-known insulin antagonist [14]. In addition, IR–IGF-IR hybrids behave like IGF-IRs but show differential IGF-I vs. IGF-II stimulated activity based upon the involved IR isoforms [19][20].
Healthy adult liver cells show a very low expression of the IGF-IR, and the IGF-IR expression in fat cells of the adipocyte tissue is also low and tends to decrease when differentiating from pre-adipocytes to mature adipocytes [21][22]. Therefore, these latter tissues, while being extremely insulin responsive, are relatively refractory to exposure to IGF-I [14]. A complex inter-relationship exists between IGF-I, insulin, and GH [23]. Hepatic IGF-I production is stimulated by both GH and insulin, while IGF-I feeds back to suppress GH and insulin secretions [23] (see further below).

4. Reaven and the Metabolic Syndrome

Reaven previously suggested that the more insulin sensitive an individual, the better off (s)he is [24]. In an insulin-sensitive individual, the beta-cell is not stressed, and glucose tolerance can be maintained at low plasma insulin levels [24]. However, he also suggested that resistance to insulin-stimulated glucose uptake is present in more than 80% of individuals with impaired glucose tolerance or type 2 diabetes, and in about 25% of nonobese individuals with normal glucose tolerance [24]. Insulin resistance, by itself, is not sufficient to produce diabetes [24]. If the pancreatic beta-cells are able to overcome insulin resistance by increasing their insulin secretory response, frank type 2 diabetes will not occur. Thus, hyperinsulinemia may prevent frank diabetes in insulin-resistant individuals. However, according to Reaven, the compensatory hyperinsulinemia to overcome insulin resistance has its own price (independent from the development of diabetes) and may produce unwanted effects [24]. In 1988, Reaven hypothesized that insulin resistance and hyperinsulinemia induce the metabolic syndrome: insulin resistance and hyperinsulinemia provide a common mechanism for the development of glucose intolerance, elevated circulating triglycerides, decreased HDL-cholesterol and hypertension [24]. In the view of Reaven, glucose intolerance, elevated circulating triglycerides, decreased HDL-cholesterol, and hypertension are more likely to occur together than separately, and when they cluster, they are highly likely to be the manifestations of resistance to insulin-stimulated glucose uptake and (compensatory) hyperinsulinemia [25]. Reaven further proposed that the metabolic syndrome plays both an important role in the etiology and clinical course of three major related conditions: hypertension, coronary artery disease and type 2 diabetes [24]. The prevalence of the metabolic syndrome varies from 8% to 67% among different populations, and it has been suggested that the variety in prevalence of the metabolic syndrome and its individual components may be related to differences in genetic background, diet, levels of physical activity, population age and sex structure, levels of over- and undernutrition, body habitus, and definitions of the metabolic syndrome [26]. Insulin resistance and hyperinsulinemia appear to be central in the development of the metabolic syndrome [27][28]. However, at present it is still unclear whether there is a unifying mechanism which causes the metabolic syndrome.

5. Causes of Hyperinsulinemia

In the view of Reaven (see above) and in most traditional literature, obesity is considered the main cause of insulin resistance. In the view of Reaven insulin resistance is the abnormality leading to hyperinsulinemia. In this model, hyperinsulinemia is a compensatory response to insulin resistance. However, an increasing number of (prospective) human studies suggests an alternative scenario: in this scenario, chronic hypersecretion of insulin is the primary abnormality leading to hyperinsulinemia and precedes, initiates, and causes insulin resistance. In this new scenario, hyperinsulinemia is the first event triggering insulin resistance, obesity, the metabolic syndrome, and type 2 diabetes [29][30][31][32][33][34][35][36][37][38][39]. In addition, in subjects with normal plasma glucose concentrations, it has been found that hyperinsulinemia per se induced insulin resistance by insulin-induced downregulation of insulin receptor signaling [40][41]. This further supports the idea that hyperinsulinemia may be a primary driver of insulin resistance [41][42]. Moreover, it has been shown that gastric bypass surgery in type 2 diabetes corrects and normalizes plasma insulin levels within some days after surgery, even though there is, at that moment, no significant weight loss (yet) and insulin resistance remains high [43]. This post-operative course clearly dissociates hyperinsulinemia from insulin resistance, further supporting the idea that hyperinsulinemia is primary, rather than a consequence occurring secondary (as a compensation) to insulin resistance [43][44].
In a well-characterized cohort of apparently healthy adults, elevated fasting insulin at baseline was found to be an independent determinant over a 5-year period for the future development of the metabolic syndrome [45]. In addition, prospective evidence shows that—independently of obesity and body weight—hyperinsulinemia is related to the development of dyslipidemia and hypertension, suggesting that hyperinsulinemia precedes these disorders in the etiologic pathway [46][47][48]. Thus, hyperinsulinemia may indeed be an early and central feature of the cardiovascular risk of subjects with the metabolic syndrome [45]. Further support of a pathogenic role of hyperinsulinemia in the development of the metabolic syndrome was demonstrated in an animal model by Jeanrenaud et al. They showed that short-term hyperinsulinemia is a pathological driving force, which produces incipient obesity by overstimulating white adipose tissue and liver metabolic activity while concomitantly producing incipient muscle insulin resistance [49].
In her Banting Lecture in 2011, Barbara Corkey proposed a model in which excessive beta-cell insulin secretory responses, possibly induced by consumption of the “modern” Western diet and over-nutrition, superimposed on a susceptible genetic background and metabolic programming, may be a major cause of hyperinsulinemia, insulin resistance, obesity, and type 2 diabetes [42]. As Corkey pointed out, many aspects of the Western diet may potentially promote hyperinsulinemia: excess nutrient ingestion, artificial sweeteners, mono-oleoylglycerol, the macronutrient ratio in the food, the characteristics of the carbohydrates, proteins and fat of the food, and insufficient dietary fiber intake [50]. In the model of Barbara Corkey, hyperinsulinemia is the dominant driver of insulin resistance. In her model, insulin resistance is an adaptive response protecting muscles from chronic hyperinsulinemia-mediated nutrient excess and intracellular hyperglycemia [42][51].
Increased activity of incretin hormones may also contribute to the development of hyperinsulinemia. Gastric inhibitory polypeptide (GIP) is an incretin hormone secreted by the gut leading to enhanced pancreatic insulin secretion after food ingestion [52]. A significant elevation of fasting GIP was found in healthy young men after five days of ingesting a Westernized diet (i.e., a diet high in fat and calories: containing 50% extra energy, where 60% of the energy came from fat (HFHC diet) [37]. In this latter study, insulin secretion was increased and preceded the development of peripheral insulin resistance, mitochondrial dysfunction, and obesity in response to overfeeding, suggesting a direct and causal role for the Westernized diet, GIP, and hyperinsulinemia in the development of peripheral insulin resistance and obesity [37].
Pancreatic insulin secretion and (hepatic) insulin clearance play distinct roles in peripheral plasma insulin concentrations. Emerging evidence suggests that not only pancreatic insulin secretion, but also lower hepatic insulin clearance, may contribute to hyperinsulinemia (=increased peripheral insulin levels). A wide variation in hepatic as well as extrahepatic insulin clearance in human subjects has been reported [53]. Hepatic insulin clearance is (at least partly) a heritable trait; several genetic variants that are involved in regulating insulin clearance have been identified in Mexican Americans, an ethnic group with a high prevalence of the metabolic syndrome and diabetes [53]. After an overnight fast, hepatic first-pass insulin extraction in Afro-Americans (AAs) was found to be only one third compared to European Americans (EA) [54].
Bergman et al. suggested the following course of events in the development of type 2 diabetes: low(ered) hepatic insulin clearance causes peripheral hyperinsulinemia, which in turn exacerbates insulin resistance [54]. Consequently, insulin resistance will stress pancreatic beta-cells, and this may finally result in their ultimate failure and onset of frank type 2 diabetes [54]. Therefore, Bergman et al. hypothesized that low(ered) hepatic insulin clearance and peripheral hyperinsulinemia can be a primary cause of type 2 diabetes in high-risk individuals [54]. In their view, development of insulin resistance in muscles and fat cells is caused by of an overexposure of the (post-hepatic) peripheral tissues to endogenous insulin [54]. As a direct consequence of the peripheral hyperinsulinemia, peripheral insulin resistance develops to dampen hyperinsulinemia-mediated stimulating effects in muscles and fat cells [54].
Reduced hepatic insulin clearance has been reported in healthy lean subjects after only three days on a diet containing high carbohydrate (80E%), low fat (9E%), and a 75% increase in daily energy calories [55]. This suggests that a high-carbohydrate, high-calorie diet may quickly and directly change hepatic insulin clearance [55]. By contrast, energy restriction induced by Roux-en-Y gastric bypass (RYGB) surgery of obese subjects with normal glucose tolerance, and obese patients with preoperatively type 2 diabetes, increased hepatic insulin clearance (=normalized) significantly within one week after operation [56].
All these studies suggest that hepatic insulin clearance is a dynamic process which can be modified (within a few days) by diets with altered energy and, particularly, carbohydrate intake. In addition, all these studies point to an important role of reduced hepatic insulin clearance as the potential culprit in the development of (peripheral) hyperinsulinemia [57].

6. The Effects of Hyperinsulinemia on the Balance of the Insulin–GH–IGF-I Axis

The insulin–growth hormone–IGF-I (insulin–GH–IGF-I) axis plays a pivotal role in metabolism. Nutrients stimulate the activity of the insulin–GH–IGF-I axis, and insulin, GH and IGF-I secretion are all nutritionally regulated [14][58]. Insulin secretion into the portal venous system is required for normal liver GH responsiveness and hepatic IGF-I synthesis and bioavailability [59]. Insulin is essential for growth hormone receptor expression in the liver and growth hormone-mediated hepatic IGF-I production [60]. There is also evidence that insulin may directly stimulate hepatic IGF-I expression [61].
Insulin (produced in the pancreas) and GH (produced in the pituitary gland) both stimulate IGF-I production in the liver, while, after secretion, IGF-I feeds back to suppress both insulin and GH secretion [60]. In healthy individuals, the insulin–GH–IGF-I axis is in balance: insulin and GH stimulate hepatic IGF-I production, whereas IGF-I secreted by the liver feeds back to suppress both insulin and GH [62][63] (Figure 1A). The typical modern Western diet can disturb this balance. Due to its continuous food intake, energy surplus, high content of sugars, corn-derived fructose syrup, saturated fats and proteins, the modern Western diet may induce hyperinsulinemia, which in turn increases IGF-I secretion [63]. Increased IGF-I subsequently induces suppression of GH secretion to lower levels than normal [64][65]. It has been found that only a few days of overeating markedly suppressed GH secretion (before any measurable weight gain) and the accompanying hyperinsulinemia is a likely mediator of this rapid reduction in GH secretion [66]. Thus, nutritionally driven hyperinsulinemia may disturb the normal balance of the insulin–GH–IGF-I axis by shifting the insulin : GH ratio towards insulin (and IGF-I) and away from GH [63] (Figure 1B). The increased insulin : GH ratio stimulates energy storage and lipid synthesis and inhibits lipid breakdown and thereby promotes obesity by promoting higher fat accumulation and lower energy expenditure [63]. Nutritionally driven disbalance of the insulin–GH–IGF-I axis may be an important etiological factor in the development of metabolic syndrome, impaired glucose tolerance and type 2 diabetes. Intriguingly, the (imbalance of the) insulin–IGF-I system is increasingly being implicated in the development of cardiovascular disease and cancer [67][68].
Ijms 24 04551 g001
Figure 1. Nutritionally driven hyperinsulinemia can disturb the normal balance of the Insulin–GH–IGF-I axis. (A) In healthy individuals, the insulin–GH–IGF-I axis is in balance: insulin and GH stimulate hepatic IGF-I production, whereas IGF-I secreted by the liver feeds back to suppress both insulin and GH. (B) The modern Western diet may induce hyperinsulinemia, which in turn increases IGF-I secretion. Increased IGF-I levels subsequently induce suppression of GH secretion to lower levels than normal. Only a few days of overeating may markedly suppress GH secretion before any measurable weight gain, and it has been suggested that, in these circumstances, the accompanying hyperinsulinemia is a likely mediator of this rapid reduction in GH secretion. Consequently, a shift of the insulin : GH ratio towards insulin (and IGF-I) and away from GH will occur. The higher insulin : GH ratio lowers energy expenditure and induces fat accumulation, thereby promoting energy storage and lipid synthesis and hindering lipid breakdown. This will promote obesity because of higher fat accumulation and lower energy expenditure (see text for more details on how the Western diet may influence the balance of the insulin–GH axis). +/green: stimulating; −/red: inhibiting. +++ strong stimulation, --- strong inhibition, ↑↑↑ marked increase, ↓↓ moderately decrease.
The effects of circulating IGF-I on the vasculature are largely modulated by IGFBPs, which control access of IGF-I to cell-surface IGF receptors [67]. IGFBP-1, one of the six IGFBPs, is believed to play an important role in glucose counter-regulation and the maintenance of normal glucose levels in normal and altered nutritional states [69]. In vitro and in vivo studies have demonstrated marked suppression of IGFBP-1 mRNA gene expression by insulin at the transcriptional level [70][71].
Circulating IGFBP-1 is inversely related to serum insulin (and IGF-I) and to pancreatic insulin secretion [72][73]. Low circulating IGFBP-1 levels may be a marker of hyperinsulinemia [73][74][75].
Low fasting IGFBP-1 levels are linked to an impaired glucose tolerance and increased cardiovascular risk and have also been suggested to play a role in the development of the metabolic syndrome [76][77][78][79].
The primary action of IGFBP-1 is to inhibit binding of IGF-I to cell membranes and thereby to reduce IGF-I bioactivity [80]. When IGFBP-1 levels are low (in case of hyperinsulinemia), IGF-I bioactivity and IGF-I-mediated effects increase and supplement the actions of insulin [69]. Conversely, when insulin levels are low (during fasting or in the late stages of type 2 diabetes), elevated IGFBP-1 levels inhibit IGF-I mediated effects [69].
Researchers previously examined a cross-sectional sub-study of a random sample of 1036 elderly subjects participating in the Rotterdam Study and found that, in subjects with normal fasting glucose (NFG) and impaired fasting glucose (IFG), circulating IGF-I bioactivity (measured by a bioassay) progressively rose with increasing insulin levels and severity of insulin resistance [65]. At fasting glucose levels just below 7.0 mmol/L, fasting insulin levels and IGF-I bioactivity reached a plateau [65]. However, in subjects with diabetes (fasting glucose > 7.0 mmol/L), fasting insulin progressively decreased with higher glucose levels, whereas IGF-I bioactivity was significantly lower than in subjects with NFG and IFG [65]. Although researchers did not measure IGFBP-1 in the study, insulin-mediated effects on IGFBP-1 may have been responsible for the observed changes in circulating IGF-I bioactivity in subjects with NFG, IFG, and diabetes (see below).
It is commonly accepted that during the natural course from normoglycemia to frank type 2 diabetes, insulin secretion follows the pattern of an inverted U, also termed ”Starling’s curve of the pancreas” (Figure 2A).
Ijms 24 04551 g002a
Ijms 24 04551 g002b
Figure 2. The changes in insulin, IGF-I bioactivity, and IGFBP-1 levels during the natural course from normoglycemia to impaired glucose intolerance and frank type 2 diabetes. (A) During the natural course from normoglycemia to frank type 2 diabetes, insulin secretion follows the pattern of an inverted U, also termed ”Starling’s curve of the pancreas”. (B) During the natural course from normoglycemia to frank type 2 diabetes, IGF-I bioactivity follows the pattern of an inverted U, suggesting that there is also a “Starling Curve” for IGF-I bioactivity. * (C) There is a U-shaped relationship between insulin and IGFBP-1 during the natural course from normoglycemia to frank type 2 diabetes **.
Although cause and effect may be difficult to assess within a cross-sectional study, the above-mentioned sub-study embedded in the Rotterdam Study showed that IGF-I bioactivity also follows the pattern of an inverted U during the natural course from NFG or IFG to diabetes, suggesting also a “Starling Curve” for IGF-I bioactivity (Figure 2B). The inverted U pattern of IGF-I bioactivity is probably caused by direct modulating effects of insulin (and IGFBP-1) on IGF-I bioactivity during the natural course from fasting normoglycemia to frank diabetes (Figure 2B). In line with the findings, Cruickshank et al. previously found a U-shaped relationship between insulin and IGFBP-1 during the natural course from normoglycemia to frank type 2 diabetes in a cross-sectional study among Europeans and Pakistanis: IGFBP-1 concentrations were lower in those with impaired compared with normal glucose tolerance, whereas IGFBP-1 rose again in those with diabetes, probably reflecting insulin arriving at the liver, the principal site of IGFBP-1 synthesis (Figure 2C) [81].

This entry is adapted from the peer-reviewed paper 10.3390/ijms24054551

References

  1. Booth, F.W.; Gordon, S.E.; Carlson, C.J.; Hamilton, M.T. Waging war on modern chronic diseases: Primary prevention through exercise biology. J. Appl. Physiol. 2000, 88, 774–787.
  2. Cordain, L.; Eaton, S.B.; Sebastian, A.; Mann, N.; Lindeberg, S.; Watkins, B.A.; O’Keefe, J.H.; Brand-Miller, J. Origins and evolution of the Western diet: Health implications for the 21st century. Am. J. Clin. Nutr. 2005, 81, 341–354.
  3. Collett-Solberg, P.F.; Cohen, P. The role of the insulin-like growth factor binding proteins and the igfbp proteases in modulating igf action. Endocrinol. Metab. Clin. N. Am. 1996, 25, 591–614.
  4. Clemmons, D.R. Role of IGF-binding proteins in regulating IGF responses to changes in metabolism. J. Mol. Endocrinol. 2018, 61, T139–T169.
  5. Belfiore, A.; Frasca, F.; Pandini, G.; Sciacca, L.; Vigneri, R. Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease. Endocr. Rev. 2009, 30, 586–623.
  6. Scalia, P.; Williams, S.J.; Fujita-Yamaguchi, Y.; Giordano, A. Cell cycle control by the insulin-like growth factor signal: At the crossroad between cell growth and mitotic regulation. Cell Cycle 2023, 22, 1–37.
  7. Scalia, P.; Giordano, A.; Williams, S.J. The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives. Cancers 2020, 12, 366.
  8. Rosenzweig, S.A. What’s new in the IGF-binding proteins? Growth Horm. IGF Res. 2004, 14, 329–336.
  9. Chan, S.J.; Cao, Q.P.; Steiner, D.F. Evolution of the insulin superfamily: Cloning of a hybrid insulin/insulin-like growth factor cDNA from amphioxus. Proc. Natl. Acad. Sci. USA 1990, 87, 9319–9323.
  10. Chan, S.; Steiner, D.F. Insulin through the ages: Phylogeny of a growth promoting and metabolic regulatory hormone. Am. Zool. 2000, 40, 213–222.
  11. Taguchi, A.; White, M.F. Insulin-Like Signaling, Nutrient Homeostasis, and Life Span. Annu. Rev. Physiol. 2008, 70, 191–212.
  12. Rinderknecht, E.; Humbel, R.E. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J. Biol. Chem. 1978, 253, 2769–2776.
  13. Jones, J.I.; Clemmons, D.R. Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions. Endocr. Rev. 1995, 16, 3–34.
  14. Clemmons, D.R. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr. Opin. Pharmacol. 2006, 6, 620–625.
  15. Janssen, J.A.; van der Lely, A.J.; Lamberts, S.W. Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity. J. Endocrinol. Investig. 2003, 26, 588–594.
  16. De Meyts, P.; Sajid, W.; Palsgaard, J.; Theede, A.-M.; Gaugain, L.; Aladdin, H.; Whittaker, J. Insulin and IGF-I Receptor Structure and Binding Mechanism; Saltiel, A.R., Pessin, J.E., Eds.; Landes Bioscience: Austin, TX, USA, 2007; pp. 1–32.
  17. Froesch, E.R.; Zapf, J. Insulin-like growth factors and insulin: Comparative aspects. Diabetologia 1985, 28, 485–493.
  18. Kiess, W.; Kessler, U.; Schmitt, S.; Funk, B. Growth hormone and insulin-like growth factor I: Basic aspects. In Growth Hormone and Insulin-Like Growth Factor-I in Human and Experimental Diabetes; Flyvbjerg, A., Orskov, H., Alberti, K.G.G.M., Eds.; John Wiley & Sons Ltd.: Chichester, UK, 1993; pp. 1–21.
  19. Pandini, G.; Frasca, F.; Mineo, R.; Sciacca, L.; Vigneri, R.; Belfiore, A. Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform Involved. J. Biol. Chem. 2002, 277, 39684–39695.
  20. Bailyes, E.M.; Navé, B.T.; Soos, M.A.; Orr, S.R.; Hayward, A.C.; Siddle, K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: Quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem. J. 1997, 327, 209–215.
  21. Caro, J.F.; Poulos, J.; Ittoop, O.; Pories, W.J.; Flickinger, E.G.; Sinha, M.K. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J. Clin. Investig. 1988, 81, 976–981.
  22. Boucher, J.; Softic, S.; El Ouaamari, A.; Krumpoch, M.T.; Kleinridders, A.; Kulkarni, R.N.; O’Neill, B.T.; Kahn, C.R. Differential Roles of Insulin and IGF-1 Receptors in Adipose Tissue Development and Function. Diabetes 2016, 65, 2201–2213.
  23. Bondy, C.A.; Underwood, L.E.; Clemmons, D.R.; Guler, H.-P.; Bach, M.A.; Skarulis, M. Clinical Uses of Insulin-like Growth Factor I. Ann. Intern. Med. 1994, 120, 593–601.
  24. Reaven, G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37, 1595–1607.
  25. Reaven, G. Metabolic syndrome: Pathophysiology and implications for management of cardiovascular disease. Circulation 2002, 106, 286–288.
  26. Cameron, A.J.; Shaw, J.E.; Zimmet, P.Z. The metabolic syndrome: Prevalence in worldwide populations. Endocrinol. Metab. Clin. N. Am. 2004, 33, 351–375.
  27. Cornier, M.-A.; Dabelea, D.; Hernandez, T.L.; Lindstrom, R.C.; Steig, A.J.; Stob, N.R.; Van Pelt, R.E.; Wang, H.; Eckel, R.H. The Metabolic Syndrome. Endocr. Rev. 2008, 29, 777–822.
  28. Liese, A.D.; Mayer-Davis, E.J.; Tyroler, H.A.; Davis, C.E.; Keil, U.; Duncan, B.B.; Heiss, G. Development of the multiple metabolic syndrome in the ARIC cohort: Joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. Ann. Epidemiol. 1997, 7, 407–416.
  29. Hoppe, C.; Mølgaard, C.; Vaag, A.; Barkholt, V.; Michaelsen, K.F. High intakes of milk, but not meat, increase s-insulin and insulin resistance in 8-year-old boys. Eur. J. Clin. Nutr. 2005, 59, 393–398.
  30. Le Stunff, C.; Bougnères, P. Early Changes in Postprandial Insulin Secretion, Not in Insulin Sensitivity, Characterize Juvenile Obesity. Diabetes 1994, 43, 696–702.
  31. Ng, Y.; Ramm, G.; James, D.E. Dissecting the Mechanism of Insulin Resistance Using a Novel Heterodimerization Strategy to Activate Akt. J. Biol. Chem. 2010, 285, 5232–5239.
  32. Rizza, R.A.; Mandarino, L.J.; Genest, J.; Baker, B.A.; Gerich, J.E. Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 1985, 28, 70–75.
  33. Del Prato, S.; Leonetti, F.; Simonson, D.C.; Sheehan, P.; Matsuda, M.; DeFronzo, R.A. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 1994, 37, 1025–1035.
  34. Weyer, C.; Hanson, R.L.; Tataranni, P.A.; Bogardus, C.; Pratley, R.E. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: Evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 2000, 49, 2094–2101.
  35. Dankner, R.; Chetrit, A.; Shanik, M.H.; Raz, I.; Roth, J. Basal state hyperinsulinemia in healthy normoglycemic adults heralds dysglycemia after more than two decades of follow up. Diabetes Metab. Res. Rev. 2012, 28, 618–624.
  36. Tricò, D.; Natali, A.; Arslanian, S.; Mari, A.; Ferrannini, E. Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents. J. Clin. Investig. 2018, 3, e124912.
  37. Brøns, C.; Jensen, C.B.; Storgaard, H.; Hiscock, N.J.; White, A.; Appel, J.S.; Jacobsen, S.; Nilsson, E.; Larsen, C.M.; Astrup, A.; et al. Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men. J. Physiol. 2009, 587, 2387–2397.
  38. Ferrannini, E.; Natali, A.; Bell, P.; Cavalloperin, P.; Lalic, N.; Mingrone, G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J. Clin. Investig. 1997, 100, 1166–1173.
  39. Kim, M.K.; Reaven, G.M.; Kim, S.H. Dissecting the relationship between obesity and hyperinsulinemia: Role of insulin secretion and insulin clearance. Obesity 2016, 25, 378–383.
  40. Schofield, C.J.; Sutherland, C. Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes. Diabet. Med. 2012, 29, 972–979.
  41. Shanik, M.H.; Xu, Y.; Škrha, J.; Dankner, R.; Zick, Y.; Roth, J. Insulin Resistance and Hyperinsulinemia: Is hyperinsulinemia the cart or the horse? Diabetes Care 2008, 31 (Suppl. 2), S262–S268.
  42. Corkey, B.E. Banting Lecture 2011: Hyperinsulinemia: Cause or Consequence? Diabetes 2011, 61, 4–13.
  43. Kelly, C.T.; Mansoor, J.; Dohm, G.L.; Chapman, W.H., 3rd; Pender, J.R.; Pories, W.J. Hyperinsulinemic syndrome: The metabolic syndrome is broader than you think. Surgery 2014, 156, 405–411.
  44. Reed, M.A.; Pories, W.J.; Chapman, W.; Pender, J.; Bowden, R.; Barakat, H.; Gavin, T.P.; Green, T.; Tapscott, E.; Zheng, D.; et al. Roux-en-Y Gastric Bypass Corrects Hyperinsulinemia Implications for the Remission of Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2011, 96, 2525–2531.
  45. Sung, K.-C.C.; Seo, M.-H.H.; Rhee, E.-J.J.; Wilson, A.M. Elevated fasting insulin predicts the future incidence of metabolic syndrome: A 5-year follow-up study. Cardiovasc. Diabetol. 2011, 10, 108.
  46. Mykkänen, L.; Kuusisto, J.; Haffner, S.M.; Pyörälä, K.; Laakso, M. Hyperinsulinemia predicts multiple atherogenic changes in lipoproteins in elderly subjects. Arter. Thromb. 1994, 14, 518–526.
  47. Charles, M.A.; Fontbonne, A.; Thibult, N.; Warnet, J.-M.; Rosselin, G.E.; Eschwege, E. Risk Factors for NIDDM in White Population: Paris Prospective Study. Diabetes 1991, 40, 796–799.
  48. Salonen, J.T.; Lakka, T.A.; Lakka, H.-M.; Valkonen, V.-P.; Everson, S.; Kaplan, G.A. Hyperinsulinemia Is Associated With the Incidence of Hypertension and Dyslipidemia in Middle-Aged Men. Diabetes 1998, 47, 270–275.
  49. Cusin, I.; Rohner-Jeanrenaud, F.; Terrettaz, J.; Jeanrenaud, B. Hyperinsulinemia and its impact on obesity and insulin resistance. Int. J. Obes. Relat. Metab. Disord. 1992, 16 (Suppl. 4), S1–S11.
  50. Simmons, A.L.; Schlezinger, J.J.; Corkey, B.E. What Are We Putting in Our Food That Is Making Us Fat? Food Additives, Contaminants, and Other Putative Contributors to Obesity. Curr. Obes. Rep. 2014, 3, 273–285.
  51. Thomas, D.D.; Corkey, B.E.; Istfan, N.W.; Apovian, C.M. Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction. J. Endocr. Soc. 2019, 3, 1727–1747.
  52. Baggio, L.L.; Drucker, D.J. Biology of Incretins: GLP-1 and GIP. Gastroenterology 2007, 132, 2131–2157.
  53. Guo, X.; Cui, J.; Jones, M.R.; Haritunians, T.; Xiang, A.H.; Chen, Y.-D.I.; Taylor, K.D.; Buchanan, T.A.; Davis, R.C.; Hsueh, W.A.; et al. Insulin clearance: Confirmation as a highly heritable trait, and genome-wide linkage analysis. Diabetologia 2012, 55, 2183–2192.
  54. Bergman, R.N.; Piccinini, F.; Kabir, M.; Kolka, C.M.; Ader, M. Hypothesis: Role of Reduced Hepatic Insulin Clearance in the Pathogenesis of Type 2 Diabetes. Diabetes 2019, 68, 1709–1716.
  55. Lundsgaard, A.-M.; Sjøberg, K.A.; Høeg, L.D.; Jeppesen, J.; Jordy, A.B.; Serup, A.K.; Fritzen, A.M.; Pilegaard, H.; Myrmel, L.S.; Madsen, L.; et al. Opposite Regulation of Insulin Sensitivity by Dietary Lipid Versus Carbohydrate Excess. Diabetes 2017, 66, 2583–2595.
  56. Bojsen-Møller, K.N.; Dirksen, C.; Jørgensen, N.B.; Jacobsen, S.H.; Serup, A.K.; Albers, P.H.; Hansen, D.L.; Worm, D.; Naver, L.; Kristiansen, V.B.; et al. Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass. Diabetes 2014, 63, 1725–1737.
  57. Bojsen-Møller, K.N.; Lundsgaard, A.-M.; Madsbad, S.; Kiens, B.; Holst, J.J. Hepatic Insulin Clearance in Regulation of Systemic Insulin Concentrations—Role of Carbohydrate and Energy Availability. Diabetes 2018, 67, 2129–2136.
  58. Ketelslegers, J.-M.; Maiter, D.; Maes, M.; Underwood, L.E.; Thissen, J.-P. Nutritional regulation of insulin-like growth factor-I. Metabolism 1995, 44, 50–57.
  59. Leung, K.-C.; Doyle, N.; Ballesteros, M.; Waters, M.J.; Ho, K.K.Y. Insulin Regulation of Human Hepatic Growth Hormone Receptors: Divergent Effects on Biosynthesis and Surface Translocation. J. Clin. Endocrinol. Metab. 2000, 85, 4712–4720.
  60. Bereket, A.; Lang, C.H.; Blethen, S.L.; Gelato, M.C.; Fan, J.; Frost, R.; Wilson, T.A. Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1995, 80, 1312–1317.
  61. Boni-Schnetzler, M.; Schmid, C.; Meier, P.J.; Froesch, E.R. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am. J. Physiol. 1991, 260, E846–E851.
  62. Hartman, M.L.; E Clayton, P.; Johnson, M.L.; Celniker, A.; Perlman, A.J.; Alberti, K.G.; Thorner, M.O. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J. Clin. Investig. 1993, 91, 2453–2462.
  63. Janssen, J. Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer. Int. J. Mol. Sci. 2021, 22, 7797.
  64. Frystyk, J.; Vestbo, E.; Skjærbaek, C.; Mogensen, C.; Ørskov, H. Free insulin-like growth factors in human obesity. Metabolism 1995, 44, 37–44.
  65. Brugts, M.P.; van Duijn, C.M.; Hofland, L.J.; Witteman, J.C.; Lamberts, S.W.; Janssen, J.A. IGF-I Bioactivity in an Elderly Population: Relation to insulin sensitivity, insulin levels, and the metabolic syndrome. Diabetes 2010, 59, 505–508.
  66. Cornford, A.S.; Barkan, A.L.; Horowitz, J.F. Rapid Suppression of Growth Hormone Concentration by Overeating: Potential Mediation by Hyperinsulinemia. J. Clin. Endocrinol. Metab. 2011, 96, 824–830.
  67. Heald, A.H.; Siddals, K.W.; Fraser, W.; Taylor, W.; Kaushal, K.; Morris, J.; Young, R.J.; White, A.; Gibson, J.M. Low Circulating Levels of Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Are Closely Associated With the Presence of Macrovascular Disease and Hypertension in Type 2 Diabetes. Diabetes 2002, 51, 2629–2636.
  68. Janssen, J.A.M.J.L.; Stolk, R.P.; Pols, H.A.P.; Grobbee, D.E.; Lamberts, S.W.J. Serum Total IGF-I, Free IGF-I, and IGFBP-1 Levels in an Elderly Population: Relation to cardiovascular risk factors and disease. Arter. Thromb. Vasc. Biol. 1998, 18, 277–282.
  69. Lee, P.; Conover, C.A.; Powell, D.R. Regulation and Function of Insulin-Like Growth Factor-Binding Protein-1. Proc. Soc. Exp. Biol. Med. 1993, 204, 4–29.
  70. Orlowski, C.C.; Ooi, G.T.; Brown, D.R.; Yang, Y.W.-H.; Tseng, L.Y.-H.; Rechler, M.M. Insulin Rapidly Inhibits Insulin-Like Growth Factor-Binding Protein-1 Gene Expression in H4-II-E Rat Hepatoma Cells. Mol. Endocrinol. 1991, 5, 1180–1187.
  71. Ooi, G.T.; Tseng, L.Y.; Tran, M.Q.; Rechler, M.M. Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol. Endocrinol. 1992, 6, 2219–2228.
  72. Brismar, K.; Gutniak, M.; Povoa, G.; Werner, S.; Hall, K. Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus. J. Endocrinol. Investig. 1988, 11, 599–602.
  73. Suikkari, A.-M.; Koivisto, V.A.; Koistinen, R.; Seppälä, M.; Yki-Järvinen, H. Dose-Response Characteristics for Suppression of Low Molecular Weight Plasma Insulin-Like Growth Factor-Binding Protein by Insulin. J. Clin. Endocrinol. Metab. 1989, 68, 135–140.
  74. Mogul, H.R.; Marshall, M.; Frey, M.; Burke, H.B.; Wynn, P.S.; Wilker, S.; Southern, A.L.; Gambert, S.R. Insulin like growth factor-binding protein-1 as a marker for hyperinsulinemia in obese menopausal women. J. Clin. Endocrinol. Metab. 1996, 81, 4492–4495.
  75. Liew, C.F.; Wise, S.D.; Yeo, K.P.; Lee, K.-O. Insulin-like growth factor binding protein-1 is independently affected by ethnicity, insulin sensitivity, and leptin in healthy, glucose-tolerant young men. J. Clin. Endocrinol. Metab. 2005, 90, 1483–1488.
  76. Gibson, J.M.; Westwood, M.; Young, R.J.; White, A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J. Clin. Endocrinol. Metab. 1996, 81, 860–863.
  77. Reinehr, T.; Kleber, M.; Toschke, A.M.; Woelfle, J.; Roth, C.L. Longitudinal association between IGFBP-1 levels and parameters of the metabolic syndrome in obese children before and after weight loss. Int. J. Pediatr. Obes. 2011, 6, 236–243.
  78. Brismar, K.; Hilding, A.; Lindgren, B. Regulation of IGFBP-1 in humans. Prog. Growth Factor Res. 1995, 6, 449–456.
  79. Heald, A.H.; Cruickshank, J.K.; Riste, L.K.; Cade, J.E.; Anderson, S.; Greenhalgh, A.; Sampayo, J.; Taylor, W.; Fraser, W.; White, A.; et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001, 44, 333–339.
  80. Borai, A.; Livingstone, C.; Ghayour-Mobarhan, M.; Abuosa, A.; Shafi, S.; Mehta, S.; Heidari, A.; Emadzadeh, A.; Wark, G.; Ferns, G. Serum insulin-like growth factor binding protein-1 (IGFBP-1) phosphorylation status in subjects with and without ischaemic heart disease. Atherosclerosis 2010, 208, 593–598.
  81. Cruickshank, J.K.; Heald, A.H.; Anderson, S.; Cade, J.E.; Sampayo, J.; Riste, L.K.; Greenhalgh, A.; Taylor, W.; Fraser, W.; White, A.; et al. Epidemiology of the insulin-like growth factor system in three ethnic groups. Am. J. Epidemiol. 2001, 154, 504–513.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback